Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design

INTRODUCTION: A critical unmet need exists for precision therapies for chronic kidney disease. GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular kidney diseases characterized by an ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Liron, Reilly, John F., Cornwall, Caitlin, Gaich, Gregory A., Gipson, Debbie S., Heerspink, Hiddo J.L., Johnson, Leslie, Trachtman, Howard, Tuttle, Katherine R., Farag, Youssef M.K., Padmanabhan, Krishna, Pan-Zhou, Xin-Ru, Woodworth, James R., Czerwiec, Frank S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484122/
https://www.ncbi.nlm.nih.gov/pubmed/34622097
http://dx.doi.org/10.1016/j.ekir.2021.07.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484122/
https://www.ncbi.nlm.nih.gov/pubmed/34622097
http://dx.doi.org/10.1016/j.ekir.2021.07.006

Ejemplares similares